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Summary: In this study, the effects of half, normal and double clinical doses of artesunate; artesunate/sulfadoxine/ 
pyrimethamine; artesunate/amodiaquine and their combinants (sulfadoxine/pyrimethamine and amodiaquine) on the 
basal serum levels of testosterone, FSH, LH and prolactin of the guinea-pig were investigated. The results of this 
study showed that the agents caused significant decreases (p<0.05) in serum testosterone level, with varying effects 
on LH, FSH and prolactin. Testosterone level was decreased by artesunate (37%), sulfadoxine/pyrimethamine 
(22%), amodiaquine (14%), artesunate/sulfadoxine/pyrimethamine (41%) and artesunate/amodiaquine (49%) at the 
clinical dose, compared to the serum levels in control animals. Furthermore, artesunate and amodiaquine also caused 
moderate decreases in the serum concentrations of LH and FSH, without an effect on prolactin. The effects of these 
agents may be due to oxidative stress on the reproductive system of the organism. 
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Introduction 
Malaria is a worldwide public health problem, 
with enormous health and economic consequences 
(WHO, 1998; Aultman et al., 2002; Sachs and 
Malaney, 2002). The disease is caused by different 
species of the genus Plasmodium (including P. 
falciparium, P. vivax, P. ovale, and P. malariae).  
The treatment of malaria has faced several 
challenges due to the development of resistance of 
the parasite (White, 1999; Wellems and Plowe, 2001; 
Yeung et al., 2004), cost and adverse effects of 
antimalarial agents (Bloland et al., 2000). Different 
classes of drugs have been developed and used for 
the treatment of the disease. In the past, the 
inexpensive and orally administered antimalarial 
drug, chloroquine, was the "gold standard" treatment. 
Unfortunately development of resistance to certain 
plasmodium strains has made chloroquine ineffective 
and almost useless for malaria treatment in some 
areas (Kofi, 1983; Djimdé et al., 2001). The present 
drugs of choice are the artemisinin and its derivatives 
which have been reported to be highly efficacious 
with minimal toxicity (Mulenga, 1998; Haynes, 
2001). Furthermore, studies have shown that 
monotherapy with the artemisinins has resulted in 
some levels of treatment failures (Price et al., 1998; 
McIntosh and Olliaro, 2000) and that drug 
combinations markedly delay the emergence of 
resistance (Curtis and Otoo, 1986; Chawira et al., 
1987).  This has therefore necessitated the use of 
combined therapy of artemisinin with other 
antimalarial agents known as the artemisinin-based 




artesunate–amodiaquine,  artemether–lumefantrine 
and artesunate–mefloquine as recommended by 
WHO.  The ACTs are particularly effective because 
of their high killing rates through their schizonticidal 
and asexual killing potentials. This potential had 
made them to become the main chemotherapeutic 
agents for malaria treatment (WHO, 1995; White, 
1999; Nosten and White, 2007).  
However, the prevalence of malaria has resulted 
in indiscriminate use, abuse and patients non-
compliance to therapeutic regimens, which could 
result in clinical toxicity of these agents. 
Furthermore, most scientific studies on artemisinins 
recorded are on the effects of artemisinin and its 
derivatives alone (monotherapy) without a correlative 
study of the combinant agents in the ACT therapy 
(Raji et al., 2005; Nwanjo et al., 2007). Finally, all 
former studies carried out were with mice and albino 
rats, without any investigations on the effects of the 
above on guinea-pigs. It is therefore in that light that 
we had carried out a toxicological correlative study 
of the effects of the artemisinin derivatives 
(artesunate), the combinant drugs (amodiaquine and 
sulfadoxine/pyrimethamine) and their combined 
therapies (ACTs) on male guinea-pigs. In summary, 
the question asked was since combine therapy (ACT) 
will result in faster and better killing of the malaria 
parasite and remission (White, 1999), will the therapy 
also result in lower or enhanced toxicity? 
 
Materials and methods 
Drugs 
All the drugs used were obtained from the 
University of Port Harcourt Teaching Hospital 
(UPTH), Port Harcourt. The artemisinin derivative 
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used was artesunate (Arinate), manufactured by 
ERFA, Rue des Cultivateurs 25, 1040 Brussels. The 
ACTs were- artesunate/sulphadoxine/ pyrimethamine 
(Farenax) and artesunate/amodiaquine (Dart)  
manufactured by Swiss Pharma Nigeria Ltd, Lagos, 
Nigeria; while the combinant drugs were 
amodiaquine (Camoquine) manufactured by Pfizer 
Afrique de I’Quest BP 3857 – Dakar R.P. Senegal 
and sulfadoxine/pyrimethamine (Fansidar) by Swiss 
Pharma Nigeria Ltd, Lagos, Nigeria. The agents were 
administered in distilled water obtained from the 
Department of Chemistry, Faculty of Sciences, 
University of Port Harcourt, Nigeria. 
 
Animals 
Outbred strains of adult male guinea-pigs (GPs) 
of average weight 450±5g were obtained from the 
animal house of the University of Port Harcourt, 
Nigeria and allowed to acclimatize for 14 days. The 
guinea-pigs were fed with alfalfa feeds and water 
daily ad libitum at a room temperature of 29±2
0
C 
with 12-h light/dark cycle. 
 
The effects on testicular hormonal parameters  
The animals were divided into six (6) groups- A, 
B, C, D, E and F of five animals each and orally 
administered with the following normal clinical doses 
of the agents. 
The animals in group A was given 2mg/kg body 
weight of artesunate 12-hourly for three days. 
Animals in group B were given 10mg base/kg body 
weight of amodiaquine once daily for three days, 
while those in group C received a single dose of 
1.25/25 mg base/kg body weight of 
sulfadoxine/pyrimethamine. The animals in group D 
were given 4 mg/kg body weight of artesunate and 
10mg base/kg body weight of amodiaquine once a 
day for 3 days. The animals in group E (which served 
as the control were given only distilled water once 
daily for three days.  
These experiments with the antimalarial agents 
were carried out simultaneously with other sets of 
animals using half and double the normal clinical 
doses of the antimalarial agents.  At the end of each 
treatment course, the animals were sacrificed and 
blood samples were collected by cardiac puncture 
and assayed for FSH, LH, prolactin and testosterone 










Data were expressed as means ± standard errors 
of mean. Comparisons between control and treated 
groups of guinea-pigs were performed with one-way 
analysis of variance (ANOVA), followed by 
Duncan’s multiple comparison test. Statistical 




In n=5, artesunate, ACTs and their combinants 
used in this experiment caused significant (p<0.05) 
decreases in the serum concentrations of testosterone, 
with varying effects on LH, FSH and prolactin. These 
effects were non-dose-dependent and generally most 
pronounced at the lower doses (subclinical and 
clinical doses), with the combination products 
(ACTs) causing non synergistic but more damaging 
inhibitory effects (Figs. 1a and b). The serum values 
obtained at the normal clinical dose with artesunate, 
sulfadoxine/pyrimethamine and amodiaquine were 
1.98±0.29, 2.45±0.41 and 2.7±0.27 ng/ml, which 
when compared to the basal serum level of 3.14±0.24 
ng/ml represented 37, 22 and 14% decreases 
respectively. These values were also very significant 
at p<0.05. However, the values for the ACTs- 
artesunate/ sulfadoxine/pyrimethamine and artesunate 
/amodiaquine were 1.85±0.87 and 1.60±0.29 (41 and 
49 % decreases) respectively, which showed 
potentiation of the effects of the individual agents 
(Figs. 1a, b and c).  
Artesunate and amodiaquine caused moderate 
decreases in the basal serum concentrations of LH 
and FSH, while the other agents had little or no effect 
on serum LH level (Figs. 2 and 3). The effects of 
artesunate on LH were significant (p<0.05) at all 
doses and most pronounced at the lower doses- half 
and normal clinical doses (Figs. 2a and b). The serum 
values obtained were 2.88±0.05 and 2.09±0.09 g/L, 
compared to the control serum value of 3.45±0.10 
g/L (Figs. 2a and b).  
Furthermore, the effects of artesunate and 
amodiaquine on FSH were significant (p<0.05) at the 
subclinical dose, decreasing basal serum FSH level 
from 2.44±0.09 to 2.03±0.09 and 2.05±0.06 g/L 
respectively (Figs. 3a and b).  Finally, half clinical 
doses of artesunate and sulfadoxine/pyrimethamine 
caused significant decreases in serum prolactin levels 
in treated animals, compared to the control animals, 
while the other agents caused no significant changes 











































































Fig. 2: The effects of antimalarial agents on serum 
Leutinizing Hormone (LH) levels of male GPs. Data 
are mean ± SEM, n=5; *Significantly different from 



















Fig. 3: The effects of antimalarial agents on the serum Follicle Stimulating Hormone (FSH) levels of male GPs. 








Artesunate, ACTs and their combinants on the hormonal parameters 
Fig. 1: The effects of antimalarial agents on serum 
testosterone levels of male GPs. Data are mean ± 
SEM, n=5; *Significantly different from control at 






















Fig. 4: The effects of antimalarial agents on serum Prolactin levesl of male GPs. Data are mean ± SEM, n=5; * 
significantly different from control at p< 0.05 ANOVA. 
 
Discussion 
Most antimalarial agents had been shown to be 
toxic to male gonadal functions (Sairam, 1978; 
Adeeko and Dada, 1998; Orisakwe, et al, 2003; Raji 
et al, 2005). Furthermore, previous studies on the 
effects of artemisinins in male reproductive 
dysfunction had been centered on single artemisinin 
agents, using mice and albino rats (Raji et al, 2005; 
Nwanjo et al, 2007). In respect of specie variation as 
it concerns drug metabolism, the present study 
investigated the comparative effects of artesunate (as 
a single agent), ACTs and the partner antimalarial 
agents (combinants) on some male reproductive 
hormones in the male guinea-pig. The study was 
intended to evaluate or assess the therapeutic indices 
of the “wonder” antimalarial regimens (ACTs) 
against single artemisinin derivatives and the 
combinants. 
In this study, artesunate decreased serum LH 
levels at all doses, amodiaquine at the double clinical 
dose, while sulfadoxine/pyrimethamine caused an 
increase at subclinical dose, without significant 
effects at the other doses. The other agents had no 
significant effects.  Furthermore, artesunate and 
amodiaquine significantly decreased serum FSH, 
while artesunate/amodiaquine and artesunate/ 
sulfadoxine /pyrimethamine caused no significant 
effects. These results indicate that artesunate 
combinations with amodiaquine and sulfadoxine/ 
pyrimethamine caused moderation of the effects of 
the individual agents on LH and FSH.  The agents 
also had no significant effects on prolactin activity. 
Furthermore, all the agents caused significant 
decreases in serum testosterone levels mostly at the 
subclinical and clinical doses of the drugs. Artesunate 
caused significant decrease in serum testosterone 
level, which is consistent with the findings of a 
similar study with artemether (Raji et al, 2005). In 
addition, sulfadoxine/ pyrimethamine, amodiaquine 
and halofantrine also caused significant decreases in 
serum testosterone level, which is also consistent 
with the observations of (Orisakwe et al, 2003). 
However, the ACTs caused greater effects compared 
to the individual agents.  
Nosten and White, (2007) had reported that 
artemisinin and its derivatives on their own are 
relatively free from toxicological effects and that any 
toxicity observed in artemisinin combination 
treatments may be due to the partner agent. This is 
inconsistent with the results of the present study, 
where the ACTs and their combinants caused very 
significant inhibition of testosterone activity, which 
could result in impaired testicular and reproductive 
function..  
Testicular function is influenced and regulated by 
testicular hormones including- testosterone, inhibin, 
estradiol, LH, FSH, prolactin etc (Christensen, 1975; 
Huang et al, 1991). The testis, which is the major 
male reproductive organ, is responsible for sperm 
production or spermatogenesis. Spermatogenesis is 
the process of transformation of male germ cells into 
spermatozoa and requires high intratesticular levels 
of testosterone, produced by the Leydig cells 
(Ganong, 2001). Furthermore, the synthesis of 
testosterone is influenced by LH, Prolactin and FSH 
(Elkington and Blackshaw, 1974). 
The marked reduction of testosterone levels by 
these agents (especially the ACTs) may be as a result 
of direct deleterious effects on the Leydig cells 
(a) (b) 
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through generation of oxidative free radicals (Jefford, 
2001), with minimal influences on LH, FSH and 
prolactin. These toxic effects may consequently cause 
impairment in spermatogenesis. We have therefore 
carried out a follow-up study to correlate these 
effects on sperm parameters in the guinea-pig. 
The antiplasmodial action of the artemisinins has 
been attributed to the generation of oxidative stress, 
because the intraerythrocytic activation of the drug 
peroxide bond by iron (II)-heme produced during 
hemoglobin degradation results in the generation of 
reactive oxygen species- ROS  (Jefford, 2001; Robert 
et al, 2002). Similarly, studies of artemisinins on 
embryonic stem-cells in mice have shown that these 
compounds raised intracellular levels of reactive 
oxygen species (Wartenberg et al, 2003). 
Furthermore, results of our earlier study (Obianime 
and Aprioku, 2009) showed that the agents also 
caused increase in the serum levels of urea which is 
indicative of oxidative process. Thus, in this study, 
the inhibition/decrease in serum testosterone level, 
which is critical for normal spermatogenesis, may be 
due to oxidative stress on the Leydig cells and other 
structures in the testis. These oxidative effects were 




The artemisinin-based combination treatments 
(ACTs)-artesunate/amodiaquine and artesunate/ 
sulfadoxine/pyrimethamine - cause  potentiation of 
the toxicological effects of the artesinin derivative 
(artesunate) and their combinants (amodiaquine and 
sulfadoxine/ pyrimethamine) on the male 
reproductive hormones of the guinea-pig. These 
effects were observed at the subclinical, normal 
clinical and double clinical doses of the agents and 
therefore call for caution in their use. A similar study 
in humans is currently in progress to evaluate the 
effects in humans.  
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